Affordable Access

Access to the full text

Evaluation of ductal carcinoma in situ grade via triple-modal molecular imaging of B7-H3 expression

Authors
  • Bachawal, Sunitha1
  • Bean, Gregory R.1
  • Krings, Gregor2
  • Wilson, Katheryne E.1
  • 1 Stanford University, School of Medicine, Stanford, CA, USA , Stanford (United States)
  • 2 University of California San Francisco, San Francisco, CA, USA , San Francisco (United States)
Type
Published Article
Journal
npj Breast Cancer
Publisher
Nature Publishing Group UK
Publication Date
Apr 29, 2020
Volume
6
Issue
1
Identifiers
DOI: 10.1038/s41523-020-0158-y
Source
Springer Nature
License
Green

Abstract

Ductal carcinoma in situ (DCIS) will account for 62,930 cases of breast cancer in 2019. DCIS is a pre-invasive lesion which may not progress to invasive carcinoma, yet surgery remains the mainstay treatment. Molecular imaging of a specific marker for DCIS grade for detection and active surveillance are critically needed to reduce potential overtreatment. First, breast cancer marker B7-H3 (CD276) expression was evaluated by immunohistochemical staining in 123 human specimens including benign epithelium (H-score 10.0 ± 8.2) and low (20.8 ± 17.7), intermediate (87.1 ± 69.5), and high (159.1 ± 87.6) grade DCIS, showing a positive association with DCIS nuclear grade (P < 0.001, AUC 0.96). Next, a murine DCIS model was combined with ultrasound molecular imaging of B7-H3 targeted microbubbles to differentiate normal glands from those harboring DCIS (n = 100, FVB/N-Tg(MMTVPyMT)634Mul, AUC 0.89). Finally, photoacoustic and fluorescence molecular imaging with an anti-B7-H3 antibody-indocyanine green conjugate were utilized for DCIS detection (n = 53). Molecular imaging of B7-H3 expression may allow for active surveillance of DCIS.

Report this publication

Statistics

Seen <100 times